Was betrifft es? Warum ist das wichtig?

In addition to having studies approved by the Ethics Committee (EC), some studies also require a Swissmedic approval. Main criteria for a Swissmedic approval are study type (e.g. ClinO, ClinO-MD) and the study risk-category.

 

The following studies require Swissmedic approval.

ClinO studies with:

 

ClinO-MD studies with:

 

ClinO and ClinO-MD combined studies category B & C

 

Note: 

  • Category A studies only need EC approval and are thus exempt from Swissmedic approval
  • Combined studies must be submitted in parallel (i.e. on the same day) to Swissmedic and EC
  • Approval from both EC and Swissmedic must be received before starting the study

Mehr

Apart from a EC and Swissmedic approval, certain studies have added approval or consulting requirements, such as ClinO:

  • Category C studies involving ionising radiation require an opinion / approval from the from the Federal Office of Public Health (FOPH)
  • Category B & C studies of gene therapy and of genetically modified or pathogenic organisms. Swissmedic submits the dossier for consideration to the respective federal offices (e.g. SECB, FOEN, FOPH).

Was muss ich befolgen?

As a SP-INV, access Swissmedic homepage where the application process is explained, including:

  • Ways to compile a Clinical Trial Application (CTA) dossier
  • Separate and specific step-by-step guidance for dossier application for IMP and IMD
  • For ClinO-MD studies, a step by step guidance on how to submit the application dossier via the electronic portal system (service eGov “eMessage”)
  • Guidance on how to submit ClinO studies (without in vitro diagnostics MD combinations) (eDoc structure) by postal mail, either with a full paper dossier or with a paperless dossier
  • Guidance on how to submit combined studies (one submission package (eDok) using the eGov Service eMessage portal)

 

Note:

  • Parallel submission to EC and Swissmedic (if applicable FOPH) is possible.
  • For ClinO category B&C studies: An application to either EC or Swissmedic requires that the application to the second authority (be it EC or Swissmedic) must be within two years after the approval of the first authority. In the event of non-compliance with this deadline, the initial approval will expire.

Mehr

If the required approval authorities could not be entered within the 2-year time period, a request for a deadline extension can be requested. This will be regarded as a substantial modification to the study.

 

ClinO studies (without MDs) are submitted by post in both paper and electronic formats:

 

Option: full paper submission:

  • Prepare a binder and include a copy of each document. File documents and include a number index
  • Comprise the registers based on “Instructions for filling the eDok_KLV folder structure”
  • Burn a CD/DVD. Use the same structure
  • Submit binders and CD/DVD by pos^t

 

Option: paperless submission:

a) Electronic submission via the Submissions eMessage portal

  • zip-file with documents in eDok folder structure

b) Electronic submission by postal mail

  • CD/DVD with the documents in the eDok folder structure
  • Confirmation form for electronic submission

Wo kann ich Hilfe anfordern?

Your local Research Support Centre can assist you with experienced staff regarding this topic

  • Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch

  • Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch

  • Bern, Department of Clinical Research (DCR), dcr.unibe.ch

  • Geneva, Clinical Research Center (CRC), crc.hug.ch

  • Lausanne, Clinical Research Center (CRC), chuv.ch

  • St. Gallen, Clinical Trials Unit (CTU), h-och.ch

  • Zürich, Clinical Trials Center (CTC), usz.ch

External Links

Swissmedic – see in particular

References

  • FOEN - Approval regarding environmental concerns 
  • SECB - Approval regarding product quality and biological safety

Swiss Law

ClinO – see in particular articles

  • Art. 23 Submission deadline to the second authority
  • Art. 30 Exemption from mandatory authorisation
  • Art. 31 Application

ClinO-MD – see in particular articles

  • Art. 7 Exemption from mandatory authorisation
  • Art. 16 Application
  • Art. 18 Studies with devices capable of emitting ionising radiation
Abkürzungen
  • BASEC – Business Administration System for Ethics Committees
  • ClinO – Clinical Trials Ordinance
  • ClinO-MD – Ordinance on Clinical Trials with Medical Devices
  • CTA – Clinical Trial Application
  • CTU – Clinical Trials Unit
  • EC – Ethics Committee
  • FOEN – Federal Office for the Environment
  • FOPH – Federal Office of Public Health
  • GMO – Genetically Modified Organisms
  • IMD – Investigational Medicinal Device
  • IMP – Investigational Medicinal Product
  • MD – Medical Device
  • SECB – Swiss Expert Committee for Biosafety
  • SP-INV – Sponsor Investigator
Development ↦ Ethics and Laws ↦ Swissmedic Application ↦ Submission
Study
Basic

Provides some background knowledge and basic definitions

Basic Monitoring
Concept

Starts with a study idea

Ends after having assessed and evaluated study feasibility

Concept Statistic Methodology
Concept Drug or Device
Development

Starts with confidence that the study is feasible

Ends after having received ethics and regulatory approval

Development Drug or Device
Set-Up

Starts with ethics and regulatory approval

Ends after successful study initiation

Set-Up Ethics and Laws
Set-Up Statistic Methodology
Set-Up Quality and Risk
Set-Up Drug or Device
Conduct

Starts with participant recruitment

Ends after the last participant has completed the last study visit

Conduct Statistic Methodology
Conduct Drug or Device
Completion

Starts with last study visit completed

Ends after study publication and archiving

Completion Drug or Device
Current Path (click to copy): Development ↦ Ethics and Laws ↦ Swissmedic Application ↦ Submission

Please note: the Easy-GCS tool is currently under construction.